James P. Dean

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir, Jennifer R. Brown, Susan O’Brien et al. · American Journal of Hematology · 2019 · 473 citations · Full text

Medicine, Oncology, Pharmacology +14

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. Burger, Paul M. Barr, Tadeusz Robak et al. · Leukemia · 2019 · 463 citations · Full text

Medicine, Oncology, Pharmacology +16

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 314 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Constantine S. Tam, John N. Allan, Tanya Siddiqi et al. · Blood · 2022 · 238 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

William G. Wierda, John N. Allan, Tanya Siddiqi et al. · Journal of Clinical Oncology · 2021 · 229 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14